Clinical Trials Logo
  1. Home
  2. Gastric Neoplasms
  3. NCT02005809

Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm — SLEGD  

Gastric Neoplasms Clinical Trial

Official title:
Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm

Clinical Trial Summary

Gastroenterologists often follow up second look endoscopy after endoscopic submucosal dissection(ESD) of gastric neoplasms because they want to prevent bleeding of procedure sites. But Goto suggested in his retrospective analysis that a second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary. So, the investigators try to identify the hypothesis prospectively in this study.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02005809
Study type Interventional
Source Kosin University Gospel Hospital
Contact Moo In Park, MD
Phone 82519905061
Email myjuyoung@hanmail.net
Status Recruiting
Phase Phase 3
Start date March 2013
Completion date March 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Active, not recruiting NCT03615326 - Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Phase 3
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT04180761 - Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer Phase 2
Terminated NCT02488746 - Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST) N/A
Completed NCT01614522 - A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 Phase 2
Recruiting NCT04535414 - Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers Phase 2
Recruiting NCT01915225 - Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Completed NCT01166490 - A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma Phase 1
Completed NCT03817866 - Chromogranin A as Blood Marker in Cancer Patients
Terminated NCT03019588 - Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) Phase 3
Completed NCT03648879 - Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome Phase 2
Not yet recruiting NCT05111444 - Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Phase 2
Recruiting NCT05152147 - A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Phase 3
Not yet recruiting NCT04949737 - Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies